More on the CRISPR patent wars
A post by statnews on the patent fights over CRISPR technology begins:
The meter is running like mad on the dispute over key patents on CRISPR genome editing. In its latest 10-Q filing with the Securities and Exchange Commission, Editas Medicine — which has licensed one of the patents in question — disclosed that it has spent $10.9 million so far this year on legal fees incurred by the Broad Institute and Harvard, mostly to defend patents awarded for CRISPR inventions by the Broad’s Feng Zhang.
Elsewhere in the post, one finds the familiar refrain "the lawyers always win":
“The thing about patent litigation is, no matter who wins, the lawyers always win,” said Sherkow. “That’s not because the attorneys are doing anything improper, but because both sides are paying their attorneys to fight vigorously. Like any war of mercenaries, their employers can call off the fight if they wish. But when both sides are invested in victory, being a soldier of fortune is lucrative.” And when someone else is footing the bill, there is little financial incentive to call off the war.
In the past, it is believed that the costs to the University of Rochester in the cox-2 patent fights were of order 10 million.